Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Thermo Fisher Scientific Inc.
TMO
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $190.8B
$522.16
▲ +1.72%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$403.36 - $643.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 20.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Comprehensive integrated platform spanning life sciences, diagnostics, and analytical instruments with unmatched breadth
- Strong brand portfolio including Thermo Scientific, Applied Biosystems, Invitrogen, and Fisher Scientific with deep customer loyalty
- Extensive global distribution network and direct sales force providing superior customer access and support
- Significant R&D investment and proprietary technology portfolio creating sustainable competitive moats
- Strategic acquisitions and scale enabling cost advantages and cross-selling opportunities across customer base
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Increasing global demand for biopharmaceutical development and personalized medicine solutions
Value
Undervalued - trading well below Life Sciences Tools peers
Momentum
Stable
+4.5% over 3m
Quality
Stable
Excellent business quality
Dividend
Token
0.35% yield
Smart-money signal
Who's buying TMO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 21, 2026
APR 23, 2026
Reported EPS of $5.44 vs $5.25 consensus (+3.6% surprise). Revenue of $11.0B vs $10.9B expected (+1.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+3.6%
Next: Apr 21, 2026
Revenue trend · last 8Q
—
—
+5%
+0%
+3%
+5%
+7%
+6%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$10.5B
$10.6B
$11.4B
$10.4B
$10.9B
$11.1B
$12.2B
$11.0B
Margins · last 8Q
Gross
40.7%
Operating
16.9%
Profit
15.0%
Wall Street consensus
9 analysts · 78% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
78%
Hold
22%
Sell
0%
Median Price Target
$600.00
▲ +14.9% vs $522.16
Latest: Piper Sandler · Jun 11, 2026
5 analysts covering